An interventional study of kou sha and Hongjin Xiaojie Capsules in Breast Hyperplasia, sponsored by Hongguo Rong. Not yet recruiting. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Hongguo Rong · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this study, epidemiological prospective real-world cohort study design was adopted. The Third Affiliated Hospital of Beijing University of Chinese Medicine and the First Hospital of Handan City, Hebei Province were selected. From the same time appointed before the study, all breast hyperplasia participants who met the admission criteria choosing Kou Sha therapy or routine treatment of western medicine were selected in the sample hospitals.The first 30 participants were included in the planned Kou Sha therapy group while the first 30 participants were included in the control group.Taking the change of the total score of breast pain (McGill Pain Questionnaire Short Form score+breast pain score) as the main curative effect index, and taking McGill pain questionnaire score, breast color ultrasound score, palpation lump score, quality of life, anxiety and depression symptoms, sleep and so on as the secondary curative effect indexes to observe the clinical effect of the method of Kou Sha therapy on breast hyperplasia. The research period is from March 2024 to May 2024.
Investigators adopte a real-world prospective cohort study design to investigate the efficacy and safety of the Kou Sha therapy in the treatment of breast hyperplasia.Kou sha on the key points of breast diseases can dredge the mammary veins, and scraping on the back of the liver, gall bladder, spleen, and stomach can loosen the liver and diarrhea, dredge the internal organs and meridians, regulate emotions, and facilitate the recovery of breast hyperplasia.
76 studies on the registry are indexed under Hyperplasia; 9 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 51 interventional studies indexed under Hyperplasia.
Browse Hyperplasia studies →This is the only study on the registry with Hongguo Rong as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
With one of the following circumstances cannot be included in this experimental study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Generally, the Kou Sha therapy group needs to kou sha 2-3 times, and after each kou sha, it is necessary to rest for 1 week or all the shas in the part fade before they can be kou sha again. The duration of treatment is 1 menstrual cycle.
Behavioral: kou sha
The control group is treated with conventional Western medicine, and according to the patient's condition, Chinese patent medicine treatment, psychological counseling and lifestyle adjustment are carried out. The duration of treatment is 1 menstrual cycle. Stop all medications during menstruation. During this period, avoid excessive fatigue and mental stimulation, and avoid spicy and irritating foods
Drug: Hongjin Xiaojie Capsules
Kou sha is one of the most important external treatments in traditional Chinese medicine. By using the kou sha to pat on specific parts of the body or acupuncture points, light or heavy slapping is carried out to produce strong vibrations to relax the meridian qi, promote local blood circulation, and achieve the effect of blood circulation and blood stasis, detoxification and evil spirits.
The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
Breast pain score
①Pain score: 0 points for no breast pain, 2 points for mild breast pain, no feeling when not deliberately felt, and no work and life are affected, 4 points for frequent but frequent breast pain that can be tolerated, and slightly affected work and life are counted as 4 points, and obvious persistent breast pain that is unbearable and difficult to work and life to carry out normally is counted as 6 points. ②Tender pain score: 0 points for no tenderness, 3 points for slight discomfort after touching and pain after repressing, 6 points for moderate tenderness after touching and aggravation of pain after repressing, obvious pain after touching and pain after slight pressing, and 9 points for unconsciously avoiding pain due to pain when the doctor examines the body. The higher the score, the worse the result.
Time frame: 1 month
Short Form McGill Pain Inquiry Scale (SF-MPQ)
The higher the score, the worse the result.The scale is divided into 3 parts: ①The pain grading index (PRI) includes 11 sensory words and 4 emotional words, and the degree is divided into 4 levels: none, mild, moderate and severe, with 0, 1, 2 and 3 points, including feeling score (0\~36 points) and emotional score (0\~9 points), and the PRI sensory score, emotional score and total score can be calculated. ②The visual analogy grading method (VAS) is a 10 cm long straight line, with the two ends representing no pain (0 points) and severe pain (10 points) respectively, in which the patient marks the degree of pain. ③The existing pain intensity (PPI) is divided into 6 grades: no pain, mild discomfort, discomfort, uncomfortable, terrible pain, and extreme pain, with a score of 0, 1, 2, 3, 4, and 5, respectively.
Time frame: 1 month
Breast color ultrasound score
The higher the score, the worse the result.Before and after treatment, color ultrasound is used to detect the thickness and echo of the breast gland, the nature and number of breast lumps, the maximum diameter of the breast lump and whether there is a blood flow signal, the number of breast duct dilation, and the number of lymph nodes with enlarged axillary lymph nodes, and the total score is calculated
Time frame: 1 month
Palpation lump score
The higher the score, the worse the result.The sum of the lump texture score, the lump distribution range score and the lump size score. 1. Texture of the lump: 0 points for not touching the obvious thickened lump, 2 points for a small number of palpable hypertrophic glands, slightly tougher for the texture, 4 points for palpable patchy thickened glands, as tough as the tip of the nose, and 6 points for palpable large thickened hard glands, as hard as touching the forehead; 2. Lump distribution range: 1 point for not palpating local thickened glands in any quadrant of the breast, 2 points for palpating in 1 or 2 quadrants, 4 points for palpating in 3 or 4 quadrants, and 6 points for palpating in 5 or more quadrants. 3. The size of the lump: 0 points for the local thickened glands or lumps that do not touch the breast, 2 points for the maximum diameter of ≤2 cm, 4 points for the maximum diameter of 2\~4 cm, and 6 points for the maximum diameter of \>4cm.
Time frame: 1 month
Depression symptoms
The higher the score, the worse the result.The Depression Self-Rating Scale (SDS) was used to assess the emotional state of the tester, and a four-level scoring method was used, with higher scores indicating more severe anxiety and depression. The total score is 80 points, which is converted into a 100-point standard score, and the sum of the standard scores of the two scales is calculated.
Time frame: 1 month
Anxiety symptoms
The higher the score, the worse the result.The Anxiety Self-Rating Scale (SAS) was used to assess the emotional state of the tester, and a four-level scoring method was used, with higher scores indicating more severe anxiety and depression. The total score is 80 points, which is converted into a 100-point standard score, and the sum of the standard scores of the two scales is calculated.
Time frame: 1 month
The quality of life rating scale (QOL)
The quality of life rating scale (QOL) is used for evaluation, which included four dimensions, including physical symptoms, mental health, physical environment, and social function, and each dimension was converted into a standard score of 0\~100 points, and the higher the score, the higher the quality of life of the patient.
Time frame: 1 month
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2024; primary completion for May 2024, 2 months later.
Of 14 interventional studies with no phase under Hyperplasia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.